

LIBERIA

Support for Human Papillomavirus Vaccine (HPV) Demonstration Programme

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Liberia

2. Vaccines grant number: 1415-LBR-19b-X
Cash support grant number: 1415-LBR-24a-Y

3. Date of Decision Letter: 21 December 2017

4. Date of the Partnership Framework Agreement: 19 August 2013

5. Programme title: HPV Demonstration Programme

6. Vaccine type: HPV

7. **Preferred product presentation and formulation of vaccine:** HPV Quadrivalent, 1 dose(s) per vial, LIQUID

8. Programme duration¹: 2014 - 2015

9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable):

	2014	2015	Total ²
HPV vaccines (US\$)	231,107	3,241	234,348
Cash Support (US\$)	198,500	25,000	223,500
Total programme Budget (US\$)	429,607	28,241	457,848

10. Vaccine introduction grant: Not applicable

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

11. **Gavi Indicative Annual Amounts:** (subject to the terms of the Partnership Framework Agreement, if applicable)³

Vaccines:

Type of supplies to be purchased with Gavi funds in each year	2014	2015
Number of HPV vaccines doses	49,300	0
Number of AD syringes	51,900	48,100
Number of safety boxes	600	550
Annual Amounts (US\$)	231,107	3,241

Cash support:

Cash support by year	2014	
Annual Amounts (US\$)	198,500	

12. Procurement agency: UNICEF

13. Self-procurement: Not applicable

14. Co-financing obligations: Not applicable

15. Operational support for campaigns: Not applicable

16. Documents to be delivered for future disbursements: Not applicable

17. Financial clarifications: Not applicable

18. Other conditions: Not applicable

On behalf of Gavi

Hind Khatib-Othman

Libot F. Ho brill

Managing Director, Country Programmes

21 December 2017

³ This is the amount that Gavi has approved.